James Ford
Publications
- Molecular profiling of gastric cancer: toward personalized cancer medicine. J Clin Oncol. 2013; (7): 838-9
- Genetic testing by cancer site: stomach. Cancer J. 2012 Jul-Aug; (4): 355-63
- Breast cancers with compromised DNA repair exhibit selective sensitivity to elesclomol. DNA Repair (Amst). 2012; (5): 522-4
- Is breast cancer a part of Lynch syndrome? Breast Cancer Res. 2012; (4): 110
- Long-term survivors of gastric cancer: a California population-based study. J Clin Oncol. 2012; (28): 3507-15
- Lupus antibody tops cancer cells. Sci Transl Med. 2012; (157): 157fs38
- Lynch syndrome in patients with colorectal cancer: finding the needle in the haystack. JAMA. 2012; (15): 1581-3
- Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells. BMC Pharmacol. 2011: 7
- Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis. Ann Intern Med. 2011; (2): 69-79
- Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin. Cancer Res. 2010; (20): 7970-80
- Defective repair of oxidative dna damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase. Cancer Res. 2009; (8): 3589-96
- Second primary breast cancer occurrence according to hormone receptor status. J Natl Cancer Inst. 2009; (15): 1058-65
- Hereditary diffuse gastric cancer: implications of genetic testing for screening and prophylactic surgery. Cancer. 2008; (7 Suppl): 1850-6
- Performance of BRCA1/2 mutation prediction models in Asian Americans. J Clin Oncol. 2008; (29): 4752-8
- CDH1 truncating mutations in the E-cadherin gene: an indication for total gastrectomy to treat hereditary diffuse gastric cancer. Ann Surg. 2007; (6): 873-9
- Molecular inversion probe analysis of gene copy alterations reveals distinct categories of colorectal carcinoma. Cancer Res. 2006; (16): 7910-9
- Opposing effects of the UV lesion repair protein XPA and UV bypass polymerase eta on ATR checkpoint signaling. EMBO J. 2006; (11): 2605-14
- Predicting and preventing hereditary colorectal cancer. JAMA. 2006; (12): 1521-3
- In vivo recruitment of XPC to UV-induced cyclobutane pyrimidine dimers by the DDB2 gene product. J Biol Chem. 2003; (47): 46906-10
- The DDB2 nucleotide excision repair gene product p48 enhances global genomic repair in p53 deficient human fibroblasts. DNA Repair (Amst). 2003; (7): 819-26
- p53 and regulation of DNA damage recognition during nucleotide excision repair. DNA Repair (Amst). 2003; (9): 947-54
- p53 responsive nucleotide excision repair gene products p48 and XPC, but not p53, localize to sites of UV-irradiation-induced DNA damage, in vivo. Carcinogenesis. 2003; (5): 843-50
- BRCA1 induces DNA damage recognition factors and enhances nucleotide excision repair. Nat Genet. 2002; (1): 180-4
- p53 and DNA damage-inducible expression of the xeroderma pigmentosum group C gene. Proc Natl Acad Sci U S A. 2002; (20): 12985-90
- Xeroderma pigmentosum p48 gene enhances global genomic repair and suppresses UV-induced mutagenesis. Mol Cell. 2000; (4): 737-44
- Expression of the p48 xeroderma pigmentosum gene is p53-dependent and is involved in global genomic repair. Proc Natl Acad Sci U S A. 1999; (2): 424-8
- Expression of wild-type p53 is required for efficient global genomic nucleotide excision repair in UV-irradiated human fibroblasts. J Biol Chem. 1997; (44): 28073-80
- Li-Fraumeni syndrome fibroblasts homozygous for p53 mutations are deficient in global DNA repair but exhibit normal transcription-coupled repair and enhanced UV resistance. Proc Natl Acad Sci U S A. 1995; (19): 8876-80
- A young woman with bilateral breast cancer: identifying a genetic cause and implications for management. J Natl Compr Canc Netw. 2013; (5): 512-7
- Seventh edition (2010) of the AJCC/UICC staging system for gastric adenocarcinoma: is there room for improvement? Ann Surg Oncol. 2013; (5): 1631-8
- Breast cancer risk factors differ between Asian and white women with BRCA1/2 mutations. Fam Cancer. 2012; (3): 429-39
- Chest wall leiomyosarcoma after breast-conservative therapy for early-stage breast cancer in a young woman with Li-Fraumeni syndrome. J Natl Compr Canc Netw. 2012; (8): 939-42
- Clinicopathologic and molecular features of sporadic early-onset colorectal adenocarcinoma: an adenocarcinoma with frequent signet ring cell differentiation, rectal and sigmoid involvement, and adverse morphologic features. Mod Pathol. 2012; (8): 1128-39
- Family history as a positive prognostic factor in gastric cancer. J Clin Oncol. 2012; (7): 683-4
- HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment. Appl Immunohistochem Mol Morphol. 2012; (1): 13-24
- Identification of a Functional In Vivo p53 Response Element in the Coding Sequence of the Xeroderma Pigmentosum Group C Gene. Genes Cancer. 2012; (2): 131-40
- Identification of a novel deletion mutant strain in Saccharomyces cerevisiae that results in a microsatellite instability phenotype. Biodiscovery. 2012; (1)
- Intensity-modulated radiotherapy for pancreatic adenocarcinoma. Int J Radiat Oncol Biol Phys. 2012; (4): e595-601
- Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines. PLoS One. 2012; (5): e33788
- A prospective study of total gastrectomy for CDH1-positive hereditary diffuse gastric cancer. Ann Surg Oncol. 2011; (9): 2594-8
- A two-antibody mismatch repair protein immunohistochemistry screening approach for colorectal carcinomas, skin sebaceous tumors, and gynecologic tract carcinomas. Mod Pathol. 2011; (7): 1004-14
- Asian ethnicity and breast cancer subtypes: a study from the California Cancer Registry. Breast Cancer Res Treat. 2011; (2): 471-8
- Intensity-modulated radiation therapy versus conventional radiation therapy for squamous cell carcinoma of the anal canal. Cancer. 2011; (15): 3342-51
- Comparison of intensity-modulated radiotherapy and 3-dimensional conformal radiotherapy as adjuvant therapy for gastric cancer. Cancer. 2010; (16): 3943-52
- Expression of p16(INK4A) but not hypoxia markers or poly adenosine diphosphate-ribose polymerase is associated with improved survival in patients with pancreatic adenocarcinoma. Cancer. 2010; (22): 5179-87
- Hereditary diffuse gastric cancer due to a previously undescribed CDH1 splice site mutation. Hum Pathol. 2010; (8): 1200-3
- Longer relative telomere length in blood from women with sporadic and familial breast cancer compared with healthy controls. Cancer Epidemiol Biomarkers Prev. 2010; (2): 605-13
- Multimodality treatment with intensity modulated radiation therapy for esophageal cancer. Dis Esophagus. 2010; (4): 300-8
- Novel treatment approaches for triple-negative breast cancer. Clin Breast Cancer. 2010: E16-22
- Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. Cancer Res. 2010; (2): 512-9
- PARP Inhibitors for the Treatment and Prevention of Breast Cancer. Curr Breast Cancer Rep. 2010; (4): 190-197
- PARP inhibitors in breast cancer. Clin Adv Hematol Oncol. 2010; (9): 629-35
- Pathological response after chemoradiation for T3 rectal cancer. Colorectal Dis. 2010; (7 Online): e24-30
- Poly(ADP-Ribose) polymerase inhibition: "targeted" therapy for triple-negative breast cancer. Clin Cancer Res. 2010; (19): 4702-10
- A BRCA2 founder mutation and seven novel deleterious BRCA mutations in southern Chinese women with breast and ovarian cancer. Breast Cancer Res Treat. 2009; (3): 683-6
- Detection of solitary humeral metastasis from pancreatic adenocarcinoma with F-18 FDG PET/CT. Clin Nucl Med. 2009; (5): 312-3
- Identification of a biomarker panel using a multiplex proximity ligation assay improves accuracy of pancreatic cancer diagnosis. J Transl Med. 2009: 105
- Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas. Cancer. 2009; (3): 665-72
- The role of the retinoblastoma/E2F1 tumor suppressor pathway in the lesion recognition step of nucleotide excision repair. DNA Repair (Amst). 2009; (7): 795-802
- Magnetic resonance galactography: a feasibility study in women with prior atypical breast duct cytology. Breast J. 2008 Mar-Apr; (2): 211-4
- Cancer risk reduction and reproductive concerns in female BRCA1/2 mutation carriers. Fam Cancer. 2008; (2): 179-86
- Characterization of the pathogenic mechanism of a novel BRCA2 variant in a Chinese family. Fam Cancer. 2008; (2): 125-33
- Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2008; (3): 678-86
- Identification of a novel p53 in-frame deletion in a Li-Fraumeni-like family. Pediatr Blood Cancer. 2008; (4): 914-6
- Identifying and Preventing High-risk Gastric Cancer Individuals With CDH1 Mutations. Ann Surg. 2008; (4): 715-716
- Microsatellite instability and mismatch repair protein defects in ovarian epithelial neoplasms in patients 50 years of age and younger. Am J Surg Pathol. 2008; (7): 1029-37
- Risk-reducing total gastrectomy for germline mutations in E-cadherin (CDH1): pathologic findings with clinical implications. Am J Surg Pathol. 2008; (6): 799-809
- Ductal pattern enhancement on magnetic resonance imaging of the breast due to ductal lavage. Breast J. 2007 May-Jun; (3): 281-6
- A carrier of both MEN1 and BRCA2 mutations: case report and review of the literature. Cancer Genet Cytogenet. 2007; (2): 89-92
- Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. JAMA. 2007; (21): 2360-72
- HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination. Proc Natl Acad Sci U S A. 2007; (49): 19482-7
- Identification of an intronic single nucleotide polymorphism leading to allele dropout during validation of a CDH1 sequencing assay: implications for designing polymerase chain reaction-based assays. Genet Med. 2007; (11): 752-60
- Reversal of stathmin-mediated resistance to paclitaxel and vinblastine in human breast carcinoma cells. Mol Pharmacol. 2007; (5): 1233-40
- A kinase-independent function of c-Abl in promoting proteolytic destruction of damaged DNA binding proteins. Mol Cell. 2006; (4): 489-99
- Colorectal Cancer Screening Clinical Practice Guidelines. J Natl Compr Canc Netw. 2006; (4): 384-420
- Genetic/familial high-risk assessment: breast and ovarian. J Natl Compr Canc Netw. 2006; (2): 156-76
- Germ line mutations of mismatch repair genes in hereditary nonpolyposis colorectal cancer patients with small bowel cancer: International Society for Gastrointestinal Hereditary Tumours Collaborative Study. Clin Cancer Res. 2006; (11 Pt 1): 3389-93
- Characterization of a recurrent germ line mutation of the E-cadherin gene: implications for genetic testing and clinical management. Clin Cancer Res. 2005; (15): 5401-9
- Ductal lavage of fluid-yielding and non-fluid-yielding ducts in BRCA1 and BRCA2 mutation carriers and other women at high inherited breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2005; (5): 1082-9
- Opinions of women with high inherited breast cancer risk about prophylactic mastectomy: an initial evaluation from a screening trial including magnetic resonance imaging and ductal lavage. Health Expect. 2005; (3): 221-33
- Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer. J Clin Oncol. 2005; (24): 5613-9
- Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2005; (2): 320-3
- Regulation of DNA damage recognition and nucleotide excision repair: another role for p53. Mutat Res. 2005; (1-2): 195-202
- Breast magnetic resonance image screening and ductal lavage in women at high genetic risk for breast carcinoma. Cancer. 2004; (3): 479-89
- Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2004; (4): 1017-21
- BRCA1 and p53: compensatory roles in DNA repair. J Mol Med (Berl). 2003; (11): 700-7
- Defective double-strand DNA break repair and chromosomal translocations by MYC overexpression. Proc Natl Acad Sci U S A. 2003; (17): 9974-9
- Functional characterization of global genomic DNA repair and its implications for cancer. Mutat Res. 2003; (2-3): 107-14
- Phase II trial of preoperative 3D conformal radiotherapy, protracted venous infusion 5-fluorouracil, and weekly CPT-11, followed by surgery for ultrasound-staged T3 rectal cancer. Int J Radiat Oncol Biol Phys. 2003; (1): 132-7
- DNA Damage, Repair, and Diseases. J Biomed Biotechnol. 2002; (2): 45
- Preoperative chemoradiation for marginally resectable adenocarcinoma of the pancreas. J Gastrointest Surg. 2001 Jan-Feb; (1): 27-35
- Adjuvant chemoradiotherapy for "unfavorable" carcinoma of the ampulla of Vater: preliminary report. Arch Surg. 2001; (1): 65-9
- Protracted venous infusion 5-fluorouracil with concomitant radiotherapy compared with bolus 5-fluorouracil for unresectable pancreatic cancer. Am J Clin Oncol. 2001; (2): 155-9
- Radiotherapy, concomitant protracted-venous-infusion 5-fluorouracil, and surgery for ultrasound-staged T3 or T4 rectal cancer. Dis Colon Rectum. 2001; (1): 52-8
- The p53-regulated cyclin-dependent kinase inhibitor, p21 (cip1, waf1, sdi1), is not required for global genomic and transcription-coupled nucleotide excision repair of UV-induced DNA photoproducts. J Biol Chem. 2001; (28): 25813-22
- Adjuvant radiotherapy and concomitant 5-fluorouracil by protracted venous infusion for resected pancreatic cancer. Int J Radiat Oncol Biol Phys. 2000; (5): 1483-7
- Decreased UV sensitivity, mismatch repair activity and abnormal cell cycle checkpoints in skin cancer cell lines derived from UVB-irradiated XPA-deficient mice. Mutat Res. 2000; (4): 285-98
- Proapoptotic p53-interacting protein 53BP2 is induced by UV irradiation but suppressed by p53. Mol Cell Biol. 2000; (21): 8018-25
- Reduced global genomic repair of ultraviolet light-induced cyclobutane pyrimidine dimers in simian virus 40-transformed human cells. Mol Carcinog. 2000; (1): 17-24
- p53-mediated DNA repair responses to UV radiation: studies of mouse cells lacking p53, p21, and/or gadd45 genes. Mol Cell Biol. 2000; (10): 3705-14
- Chemoradiotherapy in the management of localized tumors of the pancreas. Ann Surg Oncol. 1999 Jan-Feb; (1): 117-22
- Hepatitis B x protein inhibits p53-dependent DNA repair in primary mouse hepatocytes. J Biol Chem. 1998; (50): 33327-32
- Human fibroblasts expressing the human papillomavirus E6 gene are deficient in global genomic nucleotide excision repair and sensitive to ultraviolet irradiation. Cancer Res. 1998; (4): 599-603
- Role of DNA excision repair gene defects in the etiology of cancer. Curr Top Microbiol Immunol. 1997: 47-70
- Experimental reversal of P-glycoprotein-mediated multidrug resistance by pharmacological chemosensitisers. Eur J Cancer. 1996; (6): 991-1001
- P-glycoprotein-mediated multidrug resistance: experimental and clinical strategies for its reversal. Cancer Treat Res. 1996: 3-38
- Modulators of multidrug resistance. Preclinical studies. Hematol Oncol Clin North Am. 1995; (2): 337-61
- Preferential repair of ultraviolet light-induced DNA damage in the transcribed strand of the human p53 gene. Mol Carcinog. 1994; (2): 105-9
- Pharmacologic circumvention of multidrug resistance. Cytotechnology. 1993; (1-3): 171-212
- Effect of buthionine sulfoximine on toxicity of verapamil and doxorubicin to multidrug resistant cells and to mice. Cancer Res. 1991; (1): 67-72
- Modulation of resistance to alkylating agents in cancer cell by gossypol enantiomers. Cancer Lett. 1991; (1): 85-94
- Biochemical correlates of the antitumor and antimitochondrial properties of gossypol enantiomers. Mol Pharmacol. 1990; (6): 840-7
- Cellular and biochemical characterization of thioxanthenes for reversal of multidrug resistance in human and murine cell lines. Cancer Res. 1990; (6): 1748-56
- Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev. 1990; (3): 155-99
- Structural features determining activity of phenothiazines and related drugs for inhibition of cell growth and reversal of multidrug resistance. Mol Pharmacol. 1989; (1): 105-15
- Toremifene: pharmacologic and pharmacokinetic basis of reversing multidrug resistance. J Clin Oncol. 1989; (9): 1359-64
Help
Trial Administration